发明名称 |
Sonochemical induction of ABCA1 expression and compositions therefor |
摘要 |
The present invention provides compositions useful for transfecting cells (e.g., liver cells) to express ABCA1. The compositions described herein comprise a pharmaceutically acceptable aqueous carrier containing sonochemically-active microspheres together with a plasmid DNA construct encoding an active form of ABCA1 and at least one promoter for the expression thereof. Preferably, the sonochemically-active microspheres comprise, consist essentially of, or consist of gas bubbles (e.g., a fluorocarbon gas, such as octafluoropropane) encapsulated within protein-containing or lipid-containing shells (e.g., human serum albumin shells). The microspheres are disruptable by exposure to ultrasonic acoustic energy to release the encapsulated gas. |
申请公布号 |
US9101745(B2) |
申请公布日期 |
2015.08.11 |
申请号 |
US201313826066 |
申请日期 |
2013.03.14 |
申请人 |
SONOGENE LLC |
发明人 |
Coles Eric;Davidson Michael |
分类号 |
A61M37/00;A61K31/7088;A61K45/06;A61K49/22;A61K41/00;A61K48/00;A61K31/713;C12N15/00 |
主分类号 |
A61M37/00 |
代理机构 |
Olson & Cepuritis, Ltd. |
代理人 |
Olson & Cepuritis, Ltd. |
主权项 |
1. A pharmaceutical composition for increasing HDL-cholesterol levels in the blood of a patient, the composition comprising a mixture of a nucleic acid encoding an expressible open reading frame and sonochemically-active microspheres in a pharmaceutically acceptable aqueous carrier; wherein the nucleic acid of the mixture consists of a plasmid vector, the expressible open reading frame consists of an expressible open reading frame encoding the active form of ATP-binding cassette transporter A1 (ABCA1), and the plasmid vector also includes at least one sequence adapted to promote expression of the open reading frame in a mammalian cell; and wherein the sonochemically-active microspheres comprise gas bubbles encapsulated within shells comprising a protein, a lipid, or a combination thereof, the microspheres being disruptable upon exposure to ultrasonic acoustic energy to release the encapsulated gas bubbles; and wherein the composition transfects liver cells when intravenously administered to the patient while ultrasonically imaging the liver, to elicit production of an increased level of HDL-cholesterol in the blood of the patient compared to the HDL-cholesterol level in the blood of the patient prior to administering the composition. |
地址 |
Glen Ellyn IL US |